Darius Tahir, correspondent, is based in Washington, D.C., and reports on health technology with an eye toward how it helps (or doesn’t) underserved populations; how it can be used (or not) to help government’s public health efforts; and whether or not it’s as innovative as it’s cracked up to be. He joins KHN after stints with Politico, Modern Healthcar, and The Gray Sheet. He’s a graduate of Stanford University and grew up in Rochester, N.Y.
This article is republished from KHN (Kaiser Health News). Controlled substances became a little less controlled during the pandemic. That benefited both patients (for their health) and telehealth startups (to make money). Some potentially addictive medications — like buprenorphine and Adderall — are now far more available online to patients because of regulatory changes. Given […]